|

Envafolimab Clinical Trials

8 actively recruiting trials

Pipeline

Phase 1: 1Phase 2: 5Phase 3: 1Phase 1/2: 1

Top Sponsors

  • 3D Medicines (Sichuan) Co., Ltd.2
  • Tianjin Medical University Second Hospital1
  • Sun Yat-sen University1
  • Sir Run Run Shaw Hospital1
  • Shanghai 6th People's Hospital1

Indications

  • Cancer8
  • CDK12 Gene Mutation1
  • Advanced Endometrial Cancer1
  • Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma1
  • Advanced or Metastatic Solid Tumors1

Other8 trials

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Phase 1
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Phase 2
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
Phase 2
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Phase 2
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Phase 2
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Phase 3
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Phase 1/2
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.